WHAT'S KNOWN ON THIS SUBJECT:
Previous studies have shown that concomitant administration of the quadrivalent human papillomavirus vaccine with MCV4 and Tdap was generally well tolerated and did not interfere with the immune responses to the respective vaccines.
WHAT THIS STUDY ADDS:
Concomitant administration of the novel 9-valent human papillomavirus vaccine with MCV4 and Tdap, 2 vaccines that are currently recommended for routine vaccination of adolescents, did not compromise the safety, tolerability, and immunogenicity of the individual vaccines. Dr Schilling was the lead clinical author; substantially contributed to acquisition of the data, interpretation of the results, and drafting of the manuscript; and reviewed and revised the manuscript for important intellectual content; Drs Parra, Gutierrez, Restrepo, Ucros, and Engel substantially contributed to acquisition of the data and reviewed and revised the manuscript for important intellectual content; Dr Herrera substantially contributed to acquisition of the data and drafting of the manuscript and reviewed and revised the manuscript for important intellectual content; Dr Shew substantially contributed to acquisition of the data and interpretation of the results and reviewed and revised the manuscript for important intellectual content; Mr Maansson substantially contributed to analysis of the data and reviewed and revised the manuscript for important intellectual content; Ms Caldwell substantially contributed to conception, design, and planning of the study and acquisition of the data and reviewed and revised the manuscript for important intellectual content; PEDIATRICS Volume 136, number 3, September 2015 ARTICLE A 9-valent (6/11/16/18/31/33/45/ 52/58) human papillomavirus (HPV; 9vHPV) vaccine was developed to cover 7 cancer-causing HPV types (HPV 16, 18, 31, 33 , 45, 52, 58) that are together responsible for ∼90% of cervical cancers and HPV-related vulvar, vaginal, and anal cancers, and 2 HPV types (HPV 6 and 11) that are responsible for 90% of genital warts. [1] [2] [3] [4] [5] In clinical studies, the 9vHPV vaccine prevented persistent infection and disease due to the HPV vaccine types in females 16 to 26 years of age 6 ; efficacy findings were extended to girls and boys 9 to 15 years of age based on noninferior immunogenicity. 7 The 9vHPV vaccine was licensed in the United States in December 2014 under the name GARDASIL9 (Merck & Co., Inc., Kenilworth, NJ). 8 In February 2015, the Advisory Committee on Immunization Practices included GARDASIL9 in its recommendations for routine HPV vaccination of boys and girls at age 11 or 12 years and catchup vaccination in females 13 to 26 years and males 13 to 21 years not vaccinated previously. 9 Epidemiologic studies have demonstrated the acquisition of HPV soon after sexual initiation. 10 The median age of sexual debut is in the late teens (15) (16) (17) (18) (19) years) in most countries. 11 Thus, preadolescent boys and girls #15 years of age represent the ideal HPV vaccination population.
Most vaccine schedules worldwide rely on the concomitant administration of vaccines to improve the adherence to vaccination and to lower the cost of the programs, both in childhood and in adolescent vaccination. Because adolescents and adults need to maintain the protection given by several childhood vaccines, such as diphtheria, tetanus, and whooping cough, and need to be protected against Neisseria meningitidis before exposure to new populations such as those in high schools, college, or military service, etc, a booster dose of the diphtheria, tetanus, and acellular pertussis vaccines and routine vaccination for meningococcal serogroups A/C/Y/ W-135 are recommended for adolescents in several countries. 12 
METHODS

Study Population
Between October 22, 2009, and February 22, 2011, 1241 healthy boys and girls aged 11 to 15 who denied any sexual activity (and who were not planning on becoming sexually active through the course of the study) from 41 sites located in Chile (n = 100), Colombia (n = 140), Mexico (n = 200), Peru (n = 100), and the United States (n = 701) participated in the study. Reasons for exclusion from the study included pregnancy (determined by urine or serum b-human chorionic gonadotropin testing), known allergy to any vaccine component, thrombocytopenia, and immunosuppression/prior immunosuppressive therapy or previous receipt of an HPV vaccine. Subjects must not have been immunized against diphtheria, tetanus, and pertussis in the past 5 years or received a meningococcal vaccine. The study was conducted in conformity with applicable national or local requirements regarding ethical committee review, informed consent, and the protection of the rights and welfare of human subjects participating in biomedical research. An external data monitoring committee assessed safety findings throughout the study.
Study Design
This was an open-label, randomized, multicenter, comparative study. Subjects were stratified by gender (1:1 ratio) and randomly assigned to 1 of 2 vaccination groups (concomitant group [Group A] or nonconcomitant group [Group B]) in a 1:1 ratio. At day 1, subjects in Group A received the first dose of 9vHPV vaccine in the deltoid muscle of the nondominant arm and MCV4 and Tdap in the deltoid muscle of the opposite arm. Subjects in Group B received the first dose of the 9vHPV vaccine on day 1 in the nondominant arm and MCV4 and Tdap 1 month later (month 1) in the dominant arm. All subjects received the second dose of the 9vHPV vaccine at month 2 and the third dose at month 6. The compositions of the 3 vaccines have been described previously. 6, 15, 16 Blood samples were drawn immediately before vaccination at day 1, month 1, month 2 (Group B only), and month 7. Serum collected from all subjects at day 1 
Safety Measurements
All subjects received a vaccination report card (VRC) at the day 1 and months 1, 2, and 6 visits. VRCs for all the subjects were to be completed after the month-1 visit to provide a common period of follow-up even though subjects in the Group A were not vaccinated at month 1. On the VRC, the parent/guardian was asked to record (1) the subject's oral temperature in the evening of the day of each study vaccination and daily for a total of 5 days and (2) injection-site and systemic adverse events (AEs) for a total of 15 days including the day of vaccination after each study vaccination. Serious AEs were collected for the whole duration of the study regardless of causality and were followed for outcome. For all injection-site AEs, except erythema and swelling, subjects were instructed by the VRC to estimate the severity of AEs as mild (awareness of symptom but easily tolerated), moderate (discomfort enough to cause interference with usual activities), or severe (incapacitating with inability to work or do usual activity). For erythema and swelling, subjects were instructed by the VRC to measure an injection-site reaction at its greatest width ("maximum size") from edge to edge in maximum units ranging from 0 to .7 inches (17.5 cm) on the VRC, rounding up to the next unit if in between 2 units (each unit on the VRC measured ∼1 inch [2.5 cm]).
Statistical Analysis
Primary immunogenicity analyses were done "per-protocol". Subjects in perprotocol analyses for the 9vHPV vaccine analyses had to receive all 3 doses of 9vHPV vaccine within acceptable day ranges and 1 dose of MCV4 and Tdap. In addition, for per-protocol analysis for 9vHPV vaccine, subjects had to (1) have at least 1 postdose 3 serology result within acceptable day ranges; (2) in analyses for the HPV6 and HPV11 components, be seronegative to both All subjects who received at least 1 study vaccination and had follow-up data were included in safety analyses. AEs were summarized descriptively as frequencies and percentages by participant groups.
RESULTS
A total of 1254 subjects residing in Latin America and North America were screened for inclusion in this study and 1241 were randomized (621 to Group A and 620 to Group B). The numbers of subjects who were randomized, vaccinated, and completed or discontinued the study are shown in Supplemental Figure 1 . Both vaccination groups were comparable with respect to baseline demographics (Table 2) . Approximately 6.4% (79 of 1241) of patients were African American, and 1.1% (14/1241) were Asian.
The most common reason for exclusion from the per-protocol analyses was having a serum sample or result missing at 4 weeks postinjection (Table 3) . Few subjects (0.3%-4.7%) were excluded from the per-protocol analyses for 9vHPV vaccine because of testing positive for HPV on Day 1.
Month 7 anti-HPV GMTs against all HPV types were comparable in Group A and Group B, with fold differences (ie, Group A/Group B) ranging from 0.97 for HPV6 and HPV11 to 1.10 for HPV45 (Table 4 ). The noninferiority criteria for the anti-HPV GMT responses in Group A relative to Group B were achieved. Seroconversion rates were 100% for all HPV types in both groups and were noninferior in Group A compared with Group B (Table 5) .
At least 75% of subjects achieved a fourfold or higher rise in titers to N meningitidis serogroup A in both Group A and Group B, and at least 89% of subjects achieved a fourfold or higher rise in titers to N meningitidis serogroups C, Y, and W-135 in both Group A and Group B ( Table 6 ). The noninferiority criterion was met for all 4 N meningitidis serogroups. More than 99.8% of subjects in both Group A and Group B achieved a diphtheria and tetanus titer $0.1 IU/mL at 4 weeks postvaccination with Tdap. There was a 0 to 0.2 percentage point difference (Group A -Group B) in the percentage of subjects who achieved titers $0.1 IU/mL, and the noninferiority criteria for both antigens were met (Table 7) . With respect to pertussis antigens the per-protocol immunogenicity analysis also showed that anti-PT, anti-FHA, anti-PRN, and anti-FIM GMTs were noninferior in Group A compared with Group B (Table 8) .
Few subjects (∼0.2%) discontinued because of an AE, and no deaths were reported (Table 9 ). Throughout the study period, 5 subjects (0.8%) in Group A and 5 subjects (0.8%) in Group B reported nonfatal serious AEs; none were vaccine related. Regarding injection-site AEs, a higher proportion of subjects in Group A reported swelling (14.4%) at the 9vHPV vaccination site compared with Group B (9.4%), and the difference between the groups was statistically significant (P = .007; b m = number of subjects with the indicated response; N, number of subjects randomized to the respective vaccination group who received at least 1 injection; n, number of subjects contributing to the analysis. CI, confidence interval. a Group A (concomitant administration) received a 0.5-mL dose of 9vHPV vaccine at day 1, month 2, and month 6 and MCV4 and Tdap on day 1; Group B (nonconcomitant administration) received 9vHPV vaccine as above and Tdap-IPV vaccine at month 1. b P value for noninferiority ,.001 for all antigens. The noninferiority criterion for end points reported in this table was defined as statistically ,10 percentage points decrease in Group A compared with Group B. Noninferiority of percent of subjects with fourfold or greater rise in titers for N meningitidis serogroups in Group A relative to Group B was demonstrated if the lower limit of the 97.5% CI for the percentage point difference was greater than -10. b m = number of subjects with the indicated response; N, number of subjects randomized to the respective vaccination group who received at least 1 injection; n, number of subjects contributing to the analysis. CI, confidence interval. a Group A (concomitant administration) received a 0.5-mL dose of 9vHPV vaccine at day 1, month 2, and month 6 and MCV4 and Tdap on day 1; Group B (nonconcomitant administration) received 9vHPV vaccine as Group A and Tdap-IPV vaccine at month 1. b P value for non-inferiority ,0.001 for all antigens. The non-inferiority criterion for endpoints reported in this table was defined as statistically less than 10 percentage points decrease in Group A compared with Group B. Non-inferiority of percent with titer $ 0.1 IU/mL in Group A relative to Group B was demonstrated if the lower limit of the 97.5% CI for the percentage point difference was greater than 210.
9vHPV vaccine injection site after the first vaccination in the concomitant group. Injection-site swelling at the 9vHPV vaccine injection site was mostly mild to moderate in intensity. Moreover, there were few discontinuations due to an AE. Thus, the finding of increased rates of injection-site swelling is likely to be of minor clinical significance. In another study that investigated concomitant administration of 9vHPV vaccine with a diphtheria/tetanus/ pertussis/polio vaccine, more subjects also reported swelling at the 9vHPV vaccine injection site in the concomitant vaccination group. 19 This suggests that the increase in injection-site swelling may be due to the concomitant administration of diphtheria/tetanus/ pertussis antigens (rather than meningococcal antigens) with 9vHPV vaccine.
The results of this study are similar to those of a previous study of concomitant administration of the quadrivalent HPV (types 6/11/16/ 18) vaccine and MCV4 and Tdap, All subjects who received $1 injection and had follow-up data were included in the primary analysis of safety. The number and percent of subjects reporting the following were compared between Group A and Group B: systemic AEs on days 1 through 15 after any vaccination and the number of subjects reporting clinical serious AEs from days 1 to 15 after any vaccination or vaccine-related clinical serious AE at any time during the study. a Postvaccination 1 is defined as the follow-up period for safety after vaccination at day 1 and after vaccination/visit at month 1. These data represent AEs reported for the 2 vaccines combined. b Because 9vHPV vaccine was the only vaccine administered in a 3-dose regimen, AEs reported postvaccination 2 and 3 would be specific to 9vHPV vaccination. c Group A (concomitant administration) received a 0.5-mL dose of 9vHPV vaccine at day 1, month 2, and month 6 and a 0.5-mL dose of MCV4 and Tdap on day 1; Group B (nonconcomitant administration) received 9vHPV vaccine as Group A and MCV4 and Tdap at month 1. Two subjects randomized into the nonconcomitant group received 9vHPV vaccine at day 1 but did not receive MCV4 and Tdap at month 1 and are excluded from this table. . Thus, throughout the study period, there were 11 serious non-vaccine-related AEs reported for 10 subjects: 5 subjects (0.8%) in Group A and 5 subjects (0.8%) in Group B (1 subject experienced 2 serious AEs: gastroenteritis and orthostatic hypotension). All serious AEs were considered not related to any of the 3 study vaccines by the study investigators (investigators were instructed to assign causality to AEs on the basis of exposure, time course, likely cause, and consistency with the vaccine' s known profile; vaccine-related AEs were those that were determined by the investigator to be possibly, probably, or definitely vaccine related). which showed that concomitant administration of dose 1 of quadrivalent HPV vaccine and MCV4 and Tdap was generally well tolerated and did not interfere with the antibody response to any of the vaccine antigens; similar to this study, increased rates in injection-site swelling were also noted in the concomitant vaccination group. 20 The primary limitation of this study was its unblinded nature. As such, safety assessment could have been biased toward an overestimation of AEs being reported in the concomitant vaccination group because subjects who are receiving 2 injections on the same day may more likely report injection-site or systemic AEs compared with subjects who receive only 1 injection. Another limitation of this study is that the coadministration of Tdap and MCV4 was assessed only with the first dose of HPV vaccine and not with subsequent doses. All subjects who received $1 injection and had follow-up data were included in the primary analysis of safety. The number and percent of subjects reporting injection-site AEs were compared between Group A and Group B. Risk differences, 95% CIs and P values were calculated for injection site AEs between day 1 and day 5 for both groups. CI, confidence interval. a Group A (concomitant administration) received a 0.5-mL dose of 9vHPV vaccine at day 1, month 2, and month 6 and a 0.5-mL dose of MCV4 and Tdap on day 1; Group B (nonconcomitant administration) received 9vHPV vaccine as Group A and MCV4 and Tdap at month 1. Two subjects randomized into the nonconcomitant group received 9vHPV vaccine at day 1 but did not did not receive MCV4 and Tdap at month 1 and are excluded from this table.
